Nurse Practitioner Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Jasmine Harris

Nurse Practitioner, Family Memphis, TN Nurse Practitioner

NPI 1255037057 CMS profile 11436238

877 Jefferson Ave, Memphis, TN 38103

Open in the dashboard

General payments

$4,660

176 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jasmine Harris of Memphis, TN is reported in the CMS Open Payments database as having received $4,660 across 176 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,864 81
2024 General $1,718 59
2023 General $1,078 36

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jasmine Harris
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Jasmine Harris were reported at $1,864. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Jasmine Harris Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $0 $124 $35–$379 $132
2022 $0 $141 $44–$430 $149
2023 $1,078 $154 $49–$476 $160
2024 $1,718 $165 $51–$504 $164
2025 $1,864 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. ViiV Healthcare Company $1,861 58 payments
  2. Gilead Sciences, Inc. $1,540 58 payments
  3. Merck Sharp & Dohme Corporation $622 29 payments
  4. Theratechnologies Inc. $425 19 payments
  5. Janssen Biotech, Inc. $91 5 payments
  6. AbbVie, Inc. $75 5 payments
  7. Otsuka America Pharmaceutical, Inc. $25 1 payment
  8. Vertex Pharmaceuticals Incorporated $21 1 payment

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $4,660 176 payments
Products named General payments · program years 2023–2025
  1. DOVATO $1,210 35 payments
  2. PIFELTRO $622 29 payments
  3. DELSTRIGO $414 19 payments
  4. EGRIFTA $402 18 payments
  5. TROGARZO $373 17 payments
  6. Biktarvy $332 6 payments
  7. RUKOBIA $183 11 payments
  8. CABENUVA Hiv $174 8 payments
  9. CABENUVA Hiv $111 1 payment
  10. Descovy $105 1 payment
  11. Other $303 16 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 73 drugs

Part D claims

2,798

Median for Family Practice: 1,826

Drug cost

$3,552,173

Median for Family Practice: $120,094

Branded share of claims

49.6%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Biktarvy Bictegrav/Emtricit/Tenofov Ala Brand 295 $1,159,261
Genvoya Elviteg/Cob/Emtri/Tenof Alafen Brand 151 $618,810
Triumeq Abacavir/Dolutegravir/Lamivudi Brand 85 $311,427
Tivicay Dolutegravir Sodium Brand 124 $307,648
Symtuza Darunavir/Cob/Emtri/Tenof Alaf Brand 52 $230,549
Juluca Dolutegravir/Rilpivirine Brand 58 $193,868
Descovy Emtricitabine/Tenofov Alafenam Brand 69 $146,987
Complera Emtricita/Rilpivirine/Tenof Df Brand 33 $122,731
Odefsey Emtricitab/Rilpiviri/Tenof Ala Brand 29 $107,658
Prezcobix Darunavir/Cobicistat Brand 26 $63,534

The 10 drugs with the highest cost, of 73 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 1 billing codes

Paid by Medicare

$2,840

Medicare's payments for the services billed

Medicare patients

32

Average age 58

Services billed

56

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DOVATO
  • ViiV Healthcare Company $501
$501 16 —
Biktarvy
  • Gilead Sciences, Inc. $163
$163 295 —
PIFELTRO
  • Merck Sharp & Dohme Corporation $110
$110 — —
DELSTRIGO
  • Merck Sharp & Dohme Corporation $110
$110 20 —
RUKOBIA
  • ViiV Healthcare Company $108
$108 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

176 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record